Safety of ximelagatran

被引：5

作者：

Brinker, A ^{[1
]}

He, RY

Desai, M

Gelperin, K

Robie-Suh, K

机构：

[1] US FDA, Off New Drugs, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA

[2] US FDA, Off Drug Safety, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2005年 / 293卷 / 23期

关键词：

D O I：

10.1001/jama.293.23.2859-a

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2859 / 2859

页数：1

共 8 条

[1] Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690
[2] Albers GW, 2003, LANCET, V362, P1691
[3] *CDER, 2000, DRUG IND LIV TOX CLI
[4] *FDA, 2004 M FDA CARD REN
[5] Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis -: A randomized trial
Fiessinger, JN
Huisman, MV
Davidson, BL
Bounameaux, H
Francis, CW
Eriksson, H
Lundström, T
Berkowitz, SD
Nyström, P
Thorsén, M
Ginsberg, JS
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06): : 681 - 689
[6] Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement
Francis, CW
Berkowitz, SD
Comp, PC
Lieberman, JR
Ginsberg, JS
Paiement, G
Peters, GR
Roth, AW
McElhattan, J
Colwell, CW
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (18) : 1703 - 1712
[7] Ximelagatran - Promises and concerns
Gurewich, V
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06): : 736 - 739
[8] Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran
Schulman, S
Wåhlander, K
Lundström, T
Clason, SB
Eriksson, H
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (18) : 1713 - 1721